Symrise will book a mid-double-digit million-euro non-cash disposal loss in its annual financial statements 2026 after selling AmeriTerpenes, its US-based terpene ingredients operation, to Munich private equity investor Mutares for an undisclosed sum.

The signing and closing of the deal occurred simultaneously, both parties confirmed, with financial terms kept confidential. The disposal loss — once crystallized in the FY2026 books — represents an eight-figure non-cash charge, a meaningful one-time item for a publicly listed flavour and fragrance supplier.

AmeriTerpenes manufactures renewable terpene ingredients at two US sites: Jacksonville, Florida, and Colonels Island, Georgia. Its customer base spans fragrance, flavour and industrial applications, placing the business at the intersection of renewable chemistry and aroma ingredients used across personal care, food and industrial product formulations.

What does Mutares bring to the deal?

Mutares, headquartered in Munich, specializes in corporate carve-outs and operational turnarounds. Its acquisition playbook centers on taking non-core industrial assets out of larger groups, restructuring them, and either reselling or listing them. For AmeriTerpenes, that translates into a buyer with a documented track record of running standalone ingredients businesses without the capital allocation pressure of a publicly traded parent.

For Symrise, the divestiture answers a strategic question the group has been signaling: how much non-core industrial chemistry does a publicly listed flavour and fragrance group need to keep?

Why is Symrise walking away now?

Dr Jean-Yves Parisot, CEO of Symrise, framed the transaction as active shaping of the group's portfolio.

"This transaction gives a good example of how we are actively shaping Symrise for the future with continued portfolio management: AmeriTerpenes is a strong business with excellent people, longstanding customer relationships and differentiated manufacturing capabilities," Parisot said.

"We are pleased that, with Mutares, we have found an experienced owner that brings a strong operational track record in corporate carve-outs and is well-suited to support AmeriTerpenes into its future," he added.

Parisot also signaled continuity for downstream customers: "We also look forward to continuing our partnership with AmeriTerpenes and Mutares as its new owner through strategic agreements entered into as part of the transaction."

What changes for buyers and formulators?

For procurement teams sourcing terpene ingredients, the immediate question is supply continuity. Symrise has signed strategic commercial agreements with AmeriTerpenes as part of the deal, meaning existing fragrance, flavour and industrial customers should see no contract disruption at closing.

Key points for buyers at the transition:

• Manufacturing footprint unchanged at Jacksonville, Florida and Colonels Island, Georgia
• Sales contacts, technical service and quality documentation remain in place during the carve-out phase
• Long-term supply agreements between Symrise and AmeriTerpenes govern the relationship going forward

For formulators working on terpene-dependent systems — pinene, limonene, terpineol derivatives — divestiture rarely triggers reformulation work. Specification locks typically run multi-year, and Mutares' carve-out model preserves operating continuity rather than forcing a re-platforming.

What does this signal about Symrise's strategy?

The disposal sharpens Symrise's stated focus on its core growth platforms. Industrial terpene chemistry, while profitable, sat outside the consumer-facing flavour and fragrance categories the group has identified as priority. The freed management bandwidth will allow the executive team to concentrate on the segments tied most directly to Symrise's reported results.

The 2026 P&L absorption is a clean-up cost rather than a strategic setback. Watch the FY2026 annual report for confirmation of the booked loss range, and Mutares' next portfolio update for indications of AmeriTerpenes' standalone capex plan and any subsequent resale or listing track.